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AbstrACt
Introduction Cauda equina syndrome (CES) is a 
potentially devastating condition caused by compression 
of the cauda equina nerve roots. This can result in bowel, 
bladder and sexual dysfunction plus lower limb weakness, 
numbness and pain. CES occurs infrequently, but has 
serious potential morbidity and medicolegal consequences. 
This study aims to identify and describe the presentation 
and management of patients with CES in the UK.
Methods and analysis Understanding Cauda Equina 
Syndrome (UCES) is a prospective and collaborative 
multicentre cohort study of adult patients with confirmed 
CES managed at specialist spinal centres in the UK. 
Participants will be identified using neurosurgical and 
orthopaedic trainee networks to screen referrals to 
spinal centres. Details of presentation, investigations, 
management and service usage will be recorded. 
Both patient-reported and clinician-reported outcome 
measures will be assessed for 1 year after surgery. This 
will establish the incidence of CES, current investigation 
and management practices, and adherence to national 
standards of care. Outcomes will be stratified by clinical 
presentation and patient management. Accurate and up 
to date information about the presentation, management 
and outcome of patients with CES will inform standards 
of service design and delivery for this important but 
infrequent condition.
Ethics and dissemination UCES received a favourable 
ethical opinion from the South East Scotland Research 
Ethics Committee 02 (Reference: 18/SS/0047; IRAS ID: 
233515). All spinal centres managing patients with CES 
in the UK will be encouraged to participate in UCES. Study 
results will be published in medical journals and shared 
with local participating sites.
trial registration number ISRCTN16828522; Pre-results.
IntroduCtIon  
Cauda equina syndrome (CES) is a rare but 
potentially devastating condition caused 
by compression of the cauda equina nerve 
roots. This most commonly occurs due to a 
prolapsed intervertebral disc. The clinical 
syndrome includes any of bilateral sciatica, 
saddle anaesthesia, bladder, bowel or sexual 
dysfunction.1–3 The disabling nature of these 
symptoms causes significant medical and 
social morbidity and high healthcare and 
social-care costs. In addition, litigation related 
to the management of CES leads to signifi-
cant medicolegal workload and costs.1 4 5 
Due to the consequences of CES for 
patients and society, several groups have 
issued clinical guidance on standards of care 
for CES.1 6–8 However, the evidence base for 
current clinical guidance consists of small 
retrospective single-centre case series.1 9 10 
Even systematic reviews of outcomes in CES 
have included relatively few patients, with 
the largest including 464 patients.9 11 Lack 
of a clear definition of CES has hampered 
comparative analysis of historical studies, and 
different interpretations of available evidence 
have been offered.10 12 A diagnosis of CES 
encompasses patients presenting with mild 
to severe urinary and bowel symptoms, peri-
neal or perianal numbness, sexual function 
strengths and limitations of this study
 ► This UK-wide study will be the largest prospective-
ly established cohort of patients with cauda equina 
syndrome (CES).
 ► The collection of detailed clinical data will describe 
the range of presentations treated as CES in the UK 
in current practice and allow stratification of find-
ings by clinical presentation.
 ► Validated outcome measures will be used to assess 
pain, disability, and bladder, bowel and sexual func-
tions 1 year after treatment.
 ► Participant identification and recruitment will be ef-
ficiently carried out using trainee research networks 
to identify participants when referred urgently to 
specialist spinal centres.
 ► The relationship of timing of investigation and de-
compression to patient outcome will be limited by 
patient and clinician reporting of the timing of symp-
tom onset.
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disturbance or bilateral sciatica, and patients may also 
experience lower limb weakness, numbness or unilateral 
sciatica.2 3 13 Outcomes for different presentations vary 
and accurate division by presentation may help to clarify 
the understanding of outcome studies and develop care 
standards appropriate to the presentation.1 14
Retrospective case series in the UK have identified 
approximately 15–31 patients per year per specialist 
neurosurgical or spinal centre with confirmed CES.3 13 15 16 
Published estimates of the incidence of CES are fewer 
than one case per 100 000 population.17 18 However, in 
2010–2011 in England, 981 surgical decompressions were 
performed for CES,19 and the population was estimated 
at 52 234 00020 giving an incidence of 1.9 per 100 000. 
Therefore, there may be over 1000 patients managed for 
CES in the UK each year. Accurate data on the presenta-
tion and management of these patients would establish 
current management plus adherence to and feasibility of 
care-quality statements, as well as potentially informing 
the revision of guidance based on accurate and current 
data.
The British Neurosurgical Trainee Research Collabora-
tive (BNTRC) has previously successfully used a network 
of neurosurgical trainees across the UK and Ireland to 
identify cases via local tertiary referral systems in condi-
tions such as chronic subdural haematoma.21 As CES is 
managed in the UK by specialist spinal services, similar 
case ascertainment via specialist referral systems to neuro-
surgical, orthopaedic or joint spinal services provides a 
method of accurately identifying patients with CES during 
hospital admission. We propose to carry out the first 
national cohort study of the presentation and manage-
ment of CES in the UK and establish the largest prospec-
tive series of patients with CES. This will provide data on 
CES incidence, epidemiology, presentation, management 
and outcomes. This will inform the development of clin-
ical guidance and identify areas for future research in 
CES.
This prospective observational cohort study aims to:
 ► Identify the number of cases of CES in the UK in all 
collaborating centres.
 ► Describe the presenting symptoms and signs in 
patients with CES.
 ► Describe the pathways of presentation to specialist 
spinal services for patients with CES in the UK.
 ► Describe the type, timing and findings of investiga-
tions in patients with CES.
 ► Describe the medical and surgical management of 
CES.
 ► Compare current practice to standards of care for 
CES.
 ► Describe clinical outcomes for patients with CES 
using validated patient reported outcome measures 
stratified by presentation, investigation findings and 
management.
 ► Demonstrate the ability of neurosurgical and ortho-
paedic surgical trainee networks to collaborate 
successfully on a prospective cohort study.
MEthods And AnAlysIs
Understanding Cauda Equina Syndrome (UCES) is a 
prospective cohort study of patients with confirmed CES 
managed at specialist spinal centres in the UK. Cases will 
be identified by neurosurgical or orthopaedic trainees in 
each specialist centre through daily screening of tertiary 
referrals and admissions to specialist spinal services. All 
patients managed as CES by the treating team will be 
included in this study.
Data regarding timing and type of symptom onset, 
referral, investigation, management and outcome will be 
recorded anonymously on a secure database by the local 
trainee investigator during the patient’s hospital admis-
sion and after discharge. Patients' consent will be sought 
for the use of their data and they will be asked to complete 
patient-reported outcome measures representing their 
condition before surgery and up to 1 year after surgery. 
Imaging at presentation will also be collected. This 
data will be compared with care quality statements and 
published outcome data for CES. This is an observa-
tional study. No changes to routine patient care will occur 
during this study.
Participant selection
The study will recruit patients for 1 year. Cases will be 
identified from admissions to spinal units between 1 June 
2018 and 31 May 2019. The last 1-year follow-up assess-
ments will be sent to participants on 31 May 2020.
For inclusion in this study, the patient must:
 ► Be over 18 years old.
 ► Be admitted to a specialist spinal service in the UK 
between 1 June 2018 and 31 May 2019.
 ► Have capacity to provide informed consent for partic-
ipation in this study.
 ► Have a diagnosis of clinical CES and structural 
compression of the cauda equina on imaging as deter-
mined by the treating clinician.
 – Clinical CES includes any of : altered saddle sensa-
tion; bladder dysfunction; bowel dysfunction; sex-
ual dysfunction; or bilateral sciatica. This should 
be associated with radiological compression of the 
cauda equina. The cauda equina compression can 
be due to any cause, including but not limited to 
disc, tumour or infection.
There is no upper age limit as we aim to establish the 
demographics of those presenting with CES.
The exclusion criteria are:
 ► Children under 18 years of age.
 ► Patients undergoing emergent decompression for 
unilateral motor or sensory symptoms (such as foot 
drop), without clinical evidence of CES.
 ► Patients referred with suspected CES where the diag-
nosis is not confirmed;for example, patients with 
clinical symptoms and signs of CES but without radio-
logical evidence of cauda equina compression.
 ► Patients not admitted to participating spinal centres 
in the UK.
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 ► Patients admitted to a participating spinal centre 
before 1 June 2018 or after 31 May 2019.
 ► Patients who are unable to provide informed consent 
for participation in this study.
Capture-recapture methods will be used to ensure 
complete case ascertainment. In December 2018, June 
2019 and December 2019 all local investigators will check 
their case ascertainment by asking their local coding 
departments for all discharges coded as CES using the 
diagnostic code from the International Classification of 
Diseases, 10th Revision (ICD-10) G83.4 Cauda Equina 
Syndrome. Any additional patients identified through 
this method that meet the inclusion criteria will be invited 
to participate.
data collection
Data relating to presentation, hospital admission, investi-
gations and follow-up will be collected by the local trainee 
investigator. Data will be collected from the patient’s 
notes, through routine interaction with the patient as part 
of clinical care, and through interaction with other staff 
members caring for the patient. All clinical and demo-
graphic information collected for this study by the local 
investigators will be collected routinely. No extra assess-
ments will be performed.
Study participants who have consented to participate 
will also be asked to fill out details about their patient 
journey, their symptoms, patient reported outcome 
measures and service usage. These will be collected 
electronically and anonymously via the electronic data-
base and linked to the patient record. Patient reported 
outcome measures will include visual analogue scores for 
back and leg pain plus relevant sections of the Oswestry 
Disability Index,22 the neurogenic bowel dysfunction 
score,23 the short form incontinence questionnaire24 and 
the Arizona sexual experiences scale.25
All patients who are eligible for inclusion in the study 
will have basic anonymous clinical data collected as part 
of the screening log to establish participation rates and 
incidence at each centre. This will allow accurate assess-
ment of the incidence of CES. Patients who do not wish to 
participate in the study will not be contacted further for 
the completion of patient reported outcome measures.
The timing and type of clinician reported and patient 
reported data that will be collected for UCES is shown in 
figure 1:Study flow diagram.
Clinician-entered data will be entered directly into the 
database using the participant’s unique study number. 
Imaging will be reviewed on local picture   archive   and 
communication systems (PACS) and transferred to the 
study team for review. Participant questionnaires will be 
sent out by email using unique links for each participant. 
If participants do not have an email address or prefer 
to fill out questionnaires on paper, paper or telephone 
versions of the questionnaires will be used. If partici-
pants do not respond to the email invitations, they will 
be contacted to find out whether they wish to continue 
with the study and to complete the questionnaires. Where 
patient data is routinely entered into spinal databases, 
surgical and outcome data from those databases will be 
linked anonymously to the patient record by the clinical 
team using the patient’s unique identifier for that data-
base or registry.
data analysis
This study aims to establish the number of patients 
presenting with CES in the UK over 1 year. We expect 
approximately 20 patients per spinal centre per year 
depending on the population served and a total of 
approximately 600–1000 patients in 1 year across the 
UK. The incidence of CES will be established based on 
the number of patients identified at each unit and the 
catchment population of that unit. If all units in the UK 
participate, incidence will be calculated based on the UK 
population estimates. Incidence will be calculated from 
all patients identified as being eligible for the study from 
referral screening and local coding departments, even if 
they do not consent for further participation.
A descriptive analysis of the clinical and demographic 
characteristics of presenting symptoms, signs and 
outcomes of patients with CES will be performed. This 
will be determined from both clinician-reported and 
patient-reported data. CES incidence and characteristics 
will be broken down into categories such as suspected 
CES, incomplete CES, with retention CES and early 
CES, based on the clinical data. The categorical and 
quantitative findings on imaging will also be described. 
Methods of patient presentation to specialist services 
will be described. Type, timings and findings of inves-
tigations in patients presenting via different routes will 
be compared. The investigation and management of 
Figure 1 Study flow diagram. Time points for patient 
reported and clinician reported data collection in 
Understanding Cauda Equina Syndrome. (QoL: Quality of 
Life) 
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patients with CES will be described and compared with 
that laid out in current care quality standards. Propor-
tions meeting the standards will be reported. Patient 
outcomes will be assessed and analysed using both clini-
cian-reported and patient-reported outcome measures at 
6 months and 1 year. Patient outcomes will be stratified by 
demographics, presenting features, causative pathology, 
timing and findings of investigations, and timing and type 
of surgery. Patient usage of healthcare services over the 
year following diagnosis and management of CES, will be 
assessed using both patient-reported service usage and 
electronic records.
Patient and public involvement
The design and aims of this study were discussed with 
current patients being investigated for CES, and those 
who had previously been treated for CES. Patients trialled 
the questionnaires and provided feedback on the ques-
tionnaires and patient information leaflet. The length 
and content of the questionnaires and information leaflet 
were altered in response to patient feedback. All partici-
pants will receive a summary of the results of this study. 
Patients are not involved in recruitment to this study 




Once patients are identified as being eligible to partici-
pate in the study, they will be asked by a member of their 
clinical team whether they would be willing to receive 
further information about the study. For the majority of 
patients this will occur during their admission to the spinal 
unit, and the approach will be made by a member of ward 
medical or nursing staff. Once verbal consent is gained 
to give further information about the study, patients will 
be provided with the information leaflet for the study. 
Patients who indicate that they are happy to have further 
discussions regarding the study will be visited in hospital 
by a member of their clinical team to complete the written 
consent process. The person undertaking written consent 
will be adequately trained to do so, and have a good 
knowledge of the study protocol, aims and processes. The 
participant will be informed about and consent to their 
medical records being inspected by regulatory authorities 
and representatives of the sponsor. Both the participant 
and the person undertaking the consent will sign and 
date the informed consent form to confirm that consent 
has been obtained. The participant will receive a copy of 
this document and a copy will be filed in the Investigator 
Site File.
Decompression surgery for CES takes place as an emer-
gency and admissions occur at all times of day and night, 
throughout the week and weekends. Following decom-
pression, the length of stay in hospital wards may be as 
short as 1–2 days, or may be longer than a week when there 
are ongoing bladder or bowel problems. All patients will 
be given adequate time to read the information leaflet 
with a minimum time period of 6 hours. Some patients 
will be discharged prior to being identified as being 
eligible for the study. These patients will be contacted by 
telephone by a member of the clinical team and asked if 
they would be willing to receive information about the 
study by post or email. If they agree, the information 
leaflet and consent form will be sent to them, and they 
will be re-contacted to go through the consent process 
over the telephone at least 24 hours after receiving the 
information.
When participants prefer to fill out paper question-
naires or do not respond to the email link, their contact 
details (name, address and telephone number) will be 
passed to the central study team at NHS Lothian using 
the NHS email system with the consent of the patient. 
The central study team will contact the participants to 
find out whether they still wish to take part in the study. 
Those who wish to continue with the study will be sent the 
questionnaires by email, by post or they can be completed 
over the telephone with a member of the central study 
team depending on the preference of the participant. If 
participants do not wish to continue with the study, they 
will not be contacted further.
Participants are free to withdraw from the study at any 
point. If withdrawal occurs, the primary reason for with-
drawal will be documented in the participant’s electronic 
case report form. The participant will not be contacted 
any further for outcome measures but their basic anon-
ymous clinical details will be retained to allow accurate 
epidemiological assessment of the incidence of CES. If 
a patient loses capacity to consent for ongoing participa-
tion during the course of the study, the data they have 
already submitted or has already been submitted by their 
clinical team with their consent will continue to be used 
in the study, but they will not be contacted with further 
questionnaires.
data protection
All Investigators and study site staff involved with this 
study will comply with the requirements of the Data 
Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and 
will uphold the Act’s core principles. Access to collated 
participant data will be restricted to individuals from the 
research team treating the participants, representatives of 
the sponsor and representatives of regulatory authorities. 
Computers used to collate the data will have limited-ac-
cess measures via user names and passwords. Published 
results will not contain any personal data that could allow 
identification of individual participants.
All clinical details will be entered into a database hosted 
by Castor EDC. Castor EDC complies with all applicable 
laws and regulations: Good Clinical Practice (GCP), Euro-
pean Union Annex 11 and the European Data Protection 
Directive. Clinician-entered data will be entered directly 
into the database using the participant’s unique study 
number. The clinical team can only view the records of 
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patients from their own centre. Once participants have 
consented for their email addresses to be stored, these 
will be entered into the Castor database by the local clin-
ical team. The email address field is stored securely and is 
encrypted and cannot be viewed by anyone outside of the 
patient’s local centre.
All local investigators will store a copy of the link 
between the patient’s unique study number and their 
contact details, National Health Service (NHS) number, 
hospital number, Community Health Index number, 
unique identifiers for spinal databases or registries or 
other identifying details on a secure password protected 
NHS computer. Consent forms and paper completed 
questionnaires will be stored securely in a locked NHS 
office. No identifying information will be entered into the 
secure database except the email address.
All identifiable scans will be stored and transferred 
within the NHS PACS network. Only anonymised scans 
will be processed outside the NHS PACS network. Anony-
mised imaging data will be labelled only with the study 
number and stored on anonymised CDs or on encrypted 
hard drives.
data retention
All study documentation will be kept for a minimum of 
5 years from the end of the study. When the minimum 
retention period has elapsed, study documentation will 
not be destroyed without permission from the sponsor. 
The end of the study is 18 months after the enrolment of 
the last participant.
Insurance and indemnity
Sites participating in the study will be liable for clinical 
negligence and other negligent harm to individuals taking 
part in the study and covered by the duty of care owed to 
them by the sites concerned. The sponsor requires indi-
vidual sites participating in the study to arrange for their 
own insurance or indemnity in respect of these liabilities. 
Sites which are part of the UK NHS will have the benefit 
of NHS Indemnity.
Ethical review
The study will be conducted in accordance with the prin-
ciples of the International Conference on Harmonisation 
Tripartite Guideline for GCP. All researchers are encour-
aged to undertake GCP training in order to understand 
the principles of GCP. However, this is not a mandatory 
requirement. GCP training status for all investigators 
should be indicated in their respective curriculum vitaes.
Local management approvals must be in place at each 
site prior to recruitment of patients to this study. The 
most recent version of the protocol will be available on 
the website of the BNTRC at www. bntrc. org. uk. This study 
is sponsored by NHS Lothian.
Peer review
The concept for this study was selected by a panel of judges 
in an open competition for support from the BNTRC. The 
protocol has been reviewed and approved by the steering 
committee for this study and reviewed by the British Ortho-
paedic Trainees’ Association, the British Association of Spine 
Surgeons, and the BNTRC committee.
Publication
Ownership of the complete dataset arising from this study 
resides with the steering committee and the BNTRC. On 
completion of the study, the data will be analysed, tabu-
lated and a report will be prepared. A summary report of 
the study will be provided to the REC within 1 year of the 
end of the study. Local data collected as part of this study 
belongs to the local team collecting that data. The study 
report will be used for publication and presentation at 
scientific meetings. Summaries of results will also be made 
available to local investigators. Following the initial anal-
ysis and publication, study data will be made available to 
those who submit successful peer-reviewed proposals for 
use of the data to the steering committee via the BNTRC.
All local investigators who enter data for at least one case 
will be named as contributors in publications arising from 
this study and will receive a certificate of collaboration in 
this study. Authorship of publications arising from this study 
will be determined in accordance with the guidelines of the 
International Committee of Medical Journal Editors.26
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